Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic calls for rapid actions, now principally oriented to a world-wide vaccination campaign. In this study we verified if, in individuals with a previous SARS-CoV-2 infection, a single dose of messenger RNA (mRNA) vaccine would be immunologically equivalent to a full vaccine schedule in naïve individuals. Health care workers (184) with a previous SARS-CoV-2 infection were sampled soon before the second dose of vaccine and between 7 and 10 days after the second dose, the last sampling time was applied to SARS-CoV-2 naïve individuals, too. Antibodies against SARS-CoV-2 were measured using Elecsys Anti-SARS-CoV-2 S immunoassay. The study was powered for non-inferiority. We used non parametric tests and Pearson correlation test to perform inferential analysis. After a single vaccine injection, the median titer of specific antibodies in individuals with previous coronavirus disease 2019 was 30.527 U/ml (interquartile range [IQR]: 19.992-39.288) and in subjects with previous SARS-CoV-2 asymptomatic infection was 19.367.5 U/ml (IQR: 14.688-31.353) (p = .032). Both results were far above the median titer in naïve individuals after a full vaccination schedule: 1974.5 U/ml (IQR: 895-3455) (p < .0001). Adverse events after vaccine injection were more frequent after the second dose of vaccine (mean: 0.95; 95% confidence interval [CI]: 0.75-1.14 vs. mean: 1.91; 95% CI: 1.63-2.19) (p < .0001) and in exposed compared to naïve (mean: 1.63; 95% CI: 1.28-1.98 vs. mean: 2.35; 95% CI: 1.87-2.82) (p = .015). In SARS-CoV-2 naturally infected individuals a single mRNA vaccine dose seems sufficient to reach immunity. Modifying current dosing schedules would speed-up vaccination campaigns.
Keywords: COVID-19; SARS-CoV-2; humoral immunity; spike RBD; spike m-RNA vaccine.
【저자키워드】 COVID-19, SARS-CoV-2, Humoral immunity, spike RBD, spike m-RNA vaccine., 【초록키워드】 coronavirus disease, Vaccine, coronavirus, vaccination, pandemic, Health care, Immunity, mRNA vaccine, SARS-COV-2 infection, immunoassay, mRNA, non-inferiority, asymptomatic infection, single dose, Analysis, dose, humoral, interquartile range, Messenger RNA, acute respiratory syndrome, Adverse, 95% confidence interval, subject, second dose, infected individual, naïve individuals, individual, naïve, injection, U/mL, Pearson correlation, single vaccine, event, specific antibody, applied, were measured, Modifying, dosing schedule, Elecsy, immunologically, naïve individual, non parametric test, the median, vaccine injection, 【제목키워드】 SARS-COV-2 infection, SARS-CoV-2 vaccination, subject,